104 related articles for article (PubMed ID: 38716576)
1. Discovery of Glutamate Carboxypeptidase III Ligands to Compete the Uptake of [
Müller M; Lucaroni L; Favalli N; Bassi G; Neri D; Cazzamalli S; Oehler S
J Med Chem; 2024 May; 67(10):8247-8260. PubMed ID: 38716576
[TBL] [Abstract][Full Text] [Related]
2. Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics.
Lucaroni L; Georgiev T; Prodi E; Puglioli S; Pellegrino C; Favalli N; Prati L; Manz MG; Cazzamalli S; Neri D; Oehler S; Bassi G
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):957-961. PubMed ID: 36184692
[TBL] [Abstract][Full Text] [Related]
3. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
4. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
5. DNA-encoded chemical libraries enable the discovery of potent PSMA-ligands with substantially reduced affinity towards the GCPIII anti-target.
Lucaroni L; Oehler S; Georgiev T; Müller M; Bocci M; De Luca R; Favalli N; Neri D; Cazzamalli S; Prati L
Chem Sci; 2024 May; 15(18):6789-6799. PubMed ID: 38725500
[TBL] [Abstract][Full Text] [Related]
6. A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals.
Kalidindi TM; Lee SG; Jou K; Chakraborty G; Skafida M; Tagawa ST; Bander NH; Schoder H; Bodei L; Pandit-Taskar N; Lewis JS; Larson SM; Osborne JR; Pillarsetty NVK
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2642-2651. PubMed ID: 33495926
[TBL] [Abstract][Full Text] [Related]
7.
Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F
J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
[TBL] [Abstract][Full Text] [Related]
8. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
[TBL] [Abstract][Full Text] [Related]
9. Inductively Coupled Plasma Mass Spectrometry─A Valid Method for the Characterization of Metal Conjugates in View of the Development of Radiopharmaceuticals.
Wallimann RH; Schindler P; Hensinger H; Tschan VJ; Busslinger SD; Kneuer R; Müller C; Schibli R
Mol Pharm; 2023 Apr; 20(4):2150-2158. PubMed ID: 36826437
[TBL] [Abstract][Full Text] [Related]
10. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Multidose Preparation of a Ready-to-Use
Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S
Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687
[No Abstract] [Full Text] [Related]
12. First Clinicopathologic Evidence of a Non-PSMA-Related Uptake Mechanism for
Rupp NJ; Umbricht CA; Pizzuto DA; Lenggenhager D; Töpfer A; Müller J; Muehlematter UJ; Ferraro DA; Messerli M; Morand GB; Huber GF; Eberli D; Schibli R; Müller C; Burger IA
J Nucl Med; 2019 Sep; 60(9):1270-1276. PubMed ID: 30737300
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
14. Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer.
Morgenroth A; Tinkir E; Vogg ATJ; Sankaranarayanan RA; Baazaoui F; Mottaghy FM
Breast Cancer Res; 2019 Oct; 21(1):116. PubMed ID: 31640747
[TBL] [Abstract][Full Text] [Related]
15. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy, prognostic variables and clinical outcome of
Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
[TBL] [Abstract][Full Text] [Related]
17. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [
Arbuznikova D; Klotsotyra A; Uhlmann L; Domogalla LC; Steinacker N; Mix M; Niedermann G; Spohn SKB; Freitag MT; Grosu AL; Meyer PT; Gratzke C; Eder M; Zamboglou C; Eder AC
Theranostics; 2024; 14(6):2560-2572. PubMed ID: 38646643
[TBL] [Abstract][Full Text] [Related]
18. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
Ruigrok EAM; van Vliet N; Dalm SU; de Blois E; van Gent DC; Haeck J; de Ridder C; Stuurman D; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1339-1350. PubMed ID: 33094433
[TBL] [Abstract][Full Text] [Related]
19.
Banerjee SR; Kumar V; Lisok A; Chen J; Minn I; Brummet M; Boinapally S; Cole M; Ngen E; Wharram B; Brayton C; Hobbs RF; Pomper MG
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2545-2557. PubMed ID: 31399803
[TBL] [Abstract][Full Text] [Related]
20. Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of
Kranzbühler B; Salemi S; Umbricht CA; Deberle LM; Müller C; Burger IA; Hermanns T; Sulser T; Eberli D
Prostate; 2019 Sep; 79(12):1450-1456. PubMed ID: 31233227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
